Evervie Health Targets Oncology Expansion with New Equipment Deal

Evervie Health Limited has signed a Letter of Intent (LOI) to acquire 10 Harmony Linear Accelerator (LINAC) systems from Sweden-based Elekta Solutions AB, with an estimated deal value between $11 million and $15 million USD. The equipment is intended for deployment through the company's operating subsidiary, Optimus Oncology Private Limited.

Reader Takeaway: The LOI signifies a strategic pivot to healthcare, but remains non-binding until definitive agreements and financing are finalized.

What just happened

On October 20, 2026, the company officially known as Evervie Health Limited (formerly PVP Ventures) announced it has initiated the procurement of 10 high-end LINAC systems. These machines are critical for advanced radiation therapy in cancer treatment. The delivery is planned in two phases of five units each, with a target completion date by October 2028. Alongside this announcement, the company transitioned its digital presence, launching a new website to align with its recent corporate rebranding.

Why this matters

This move represents the first major infrastructure commitment under the company's new identity as a healthcare-focused entity. By securing a clear path to oncology hardware, Evervie Health is signaling its intent to build out a nationwide network for cancer care. The phased delivery approach suggests a planned, long-term capital expenditure strategy rather than an immediate liquidity drain.

Risks to watch

Investors must distinguish between an LOI and a binding contract. The current arrangement is a statement of intent and is not yet a legally enforceable sale agreement. Finalization is dependent on several hurdles, including the execution of a definitive Purchase and License Agreement, securing necessary regulatory clearances, and final financing arrangements. Furthermore, the contract value is denominated in Swedish Krona (SEK), exposing the project to potential foreign exchange fluctuations.

What to track next

Shareholders should monitor the company’s disclosures for the signing of the formal purchase agreement. Additionally, updates regarding the financing structure of this $11M-$15M project will be critical to understanding how the company intends to manage its cash flow while scaling these operations.